The last word on the paclitaxel controversy
The meta-analysis of Katsanos et al in JAHA suggests the need for a reappraisal of paclitaxel-coated balloons and paclitaxel-eluting stents. CX 2019 will carry out an in-depth independent review of the benefits of paclitaxel in reducing restenosis versus the concerns of increased mortality raised by Katsanos. An open discussion will follow in front of a number of key regulatory bodies including the FDA, MHRA and BPharm.
Be part of the vascular community that decides the future use of paclitaxel in the management of peripheral vascular disease.
View the video here.
Draft UK NICE AAA guidelines
The whole of the future of endovascular aortic intervention is under review following the publication of the draft NICE AAA guidelines. Roger Greenhalgh, PI of the UK EVAR trials on which the draft NICE AAA guidelines are largely based, will propose a new follow-up method to avoid secondary sac rupture and death in a novel way that makes the case for EVAR as the cost-effective standard of care.
View the video here.
Next step in Stroke from Thoracic Endovascular Procedures (STEP) Study
STEP study investigators share latest findings to reduce the risk of stroke following complex thoracic endovascular procedures.
NEW First VIRTUAL REALITY live aortic and peripheral arterial cases
CX 2019 will feature the groundbreaking first ever VIRTUAL REALITY live aortic and peripheral arterial cases, creating a novel and completely immersive educational experience.
NEW iWounds programme and workshop
The brand new iWounds village will feature hands-on activities and edited cases to cover wound management for wounds caused by vascular (venous and peripheral arterial disease) and non-vascular conditions (diabetes).
Click Here to register today!
